Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

Rolling the dice naturally

Article Abstract:

Steve Chang, pharmacist and co-owner of Essential Elements, says that his company has a good chance of competing with large drugstore chains such as CVS, Rite Aid and Eckerd. The company, which he and Jeff Reses established in Northfield, NJ, in Dec 1997, is a combination of a natural food store and a pharmacy. The natural food store, which carries vitamins, herbs, homeopathic and a variety of natural foods, is located at the front end of the establishment, while the pharmacy is at the rear.

Author: Colchamiro, Russ
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Management, Cover Story, Drugstores, Chang, Steve, Essential Elements

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Lilly readies a 'purer' Prozac; Barr is challenging current patent with lawsuit

Article Abstract:

Eli Lilly's $90 million acquisition of the development and marketing rights for a purified version of Prozac from Sepracor could enable it to continue its domination of the antidepressant market in the 21st century. Eli Lilly's Prozac patents will expire in 2003 while Sepracor's patent for the purified version will expire in 2015. BARR Laboratories has filed a lawsuit disputing the validity of existing Prozac patents with the intention of marketing its generic version of the drug.

Author: Colchamiro, Russ
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Cases, Eli Lilly and Co., Licensing agreements, Intellectual property, Antidepressants, Patents, BRL, LLY, Prozac (Medication), Sepracor Inc., SEPR, Barr Laboratories Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Avelox touted to beat bacteria

Article Abstract:

Bayer AG is highly optimistic about the future prospects of its new antibiotic to treat several respiratory tract infections. The generic name of the drug, called Avelox, is moxifloxacin. Its range of use is quite promising and early clinical evidence suggests that it will be less prone to bacterial resistance than other similar antibiotics. Bayer expects the drug to be approved by regulators in Germany in Apr 1999 and in the US later in the year.

Author: Colchamiro, Russ
Publisher: American Druggist, Inc.
Publication Name: American Druggist
Subject: Retail industry
ISSN: 0190-5279
Year: 1999
Evaluation, Product development, Pharmaceutical industry, Antibiotics, Anti-infective agents, Drug therapy, Bayer AG, Respiratory tract infections, BAYZY

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Similar abstracts:
  • Abstracts: On the waterfront. Welcome to expatriate country. Raising the roof about bad loft extensions
  • Abstracts: Taxing time for Europe. Brown urged to increase taxes on the rich
  • Abstracts: Funds for the future Keep to the Left - for that feel-bad factor
  • Abstracts: You ask the questions. Ol' red eyes is back
  • Abstracts: Blinded by the light. Should I stay or go?
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.